PharmaBro vs Rimo: the 2026 comparison

Both refuse the revenue share. Both put the merchant account in the brand's name. Both handle LegitScript rather than leaving you to file it. Both open in days, not months.

That combination is rarer than it should be. If your shortlist is these two, you are choosing between two correct answers.

Unlimited brands from one account. Rimo caps this. If you run weight loss and TRT and hair as separate brands on separate domains — the standard portfolio play — PharmaBro is one contract and one $5,000 Scale fee covering all of them.

An in-house rebill engine instead of Stripe recurring. Tokenised cards, ship-date billing, smart retries, card account updater, and routing across up to five merchant IDs. At $100,000 MRR that recovers $500 to $1,000 a month — $6,000 to $12,000 a year Rimo's Stripe-based billing leaves on the table.

Rebill forecasting. You see next month's expected collections, the failure cohort, and the recovery curve before the cycle runs. That is a planning tool, not a report.

Rimo has the longest operator track record in the flat-fee category — 70-plus brands, most of them arriving by word of mouth, which is the only referral source that cannot be bought.

If you are launching one brand and never intend to launch a second, that track record is a real reason to choose them and the capacity advantages above will not apply to you.

One brand, one domain, no plans to expand: these are close enough that either is defensible. A portfolio, or serious subscription volume where recovered payments matter: PharmaBro's ceiling is higher and its billing recovers money Rimo's does not.

Published pricing. Your own Stripe. Zero revenue share. Live in 5 days. Unlimited brands, and forecasting that tells you what next cycle collects.